期刊文献+

中药联合地西他滨治疗高危型骨髓增生异常综合征临床观察 被引量:7

Clinical Efficacy of Chinese Medicine Combined with Decitabine in Treatment of High Risk Myelodysplastic Syndromes
下载PDF
导出
摘要 目的:探讨中药联合地西他滨治疗高危型骨髓增生异常综合征(MDS)的临床疗效观察,并与单用地西他滨组的治疗对照。方法:收集近3年在医院血液科治疗的高危型MDS患者30例,静滴地西他滨20 mg/(m2·d),连用5 d,观察组在使用地西他滨的基础上联合中草药治疗,测评治疗前后外周血象、完全缓解率及其疗效、不良反应,对比两组治疗的差异。观察地西他滨治疗高危型MDS的总体疗效及安全性。结果:观察组临床完全缓解率18.75%,单用西药组为21.42%,两组无明显统计学差异。观察组能够改善药物不良反应,相较于单用西药组,能明显改善"感染率"、"ANC时间"、"Plt减少时间","临床出血症状","消化道反应"、"口腔黏膜炎",提高患者生活质量。结论:中药联合地西他滨治疗高危型MDS患者,能明显改善药物不良反应,减少并发症,疗效安全持久。 Objective:To assess the clinical efficacy of Chinese medicine combined with decitabine for the treatment of patients with high risk myelodysplastic syndromes ( MDS), and compare with single western medicine group. Methods : Thirty consecutive patients with high - risk MDS were enrolled from Shuguang Hospital in recent three years and were treated with 5 -day decitabine intravenous injection ( 20 mg/m2, once a day) . Observation group added Chinese medi- cine treatment. Before and after treatment, the peripheral blood routines, clinical complete remission rate and its efficacy and adverse reactions were evaluated for the analysis and comparison of differences in treatment of the two groups. The effect and safety of decitabine in the treatment of high - risk - of myelodysplastic syndrome were observed. Results : Chi- nese medicine group' s clinical full mitigation rate was 18.75%, and that of signle Western medicine group was 21.42%. The two groups had no significant statistical difference. Chinese medicine combined with decitabine for the treatment of patients with high risk myelodysplastic syndromes (MDS) can improve drug side effects and can obviously improve infec- tion rate,ANC time, PLT reduced time, clinical bleeding symptoms, digestive road reaction and oral mucosa inflammatory, and can improve patients' life quality. Conclusion : Combined with decitabine in the treatment of traditional Chinese medi- cine in patients with high -risk MDS can significantly reduce adverse reactions,reduce complications and the effect is of persistent security.
出处 《中华中医药学刊》 CAS 2014年第5期1240-1243,共4页 Chinese Archives of Traditional Chinese Medicine
关键词 骨髓增生异常综合征 中药 地西他滨 去甲基化 myelodysplastic syndrome traditional Chinese medicine decitabine demethylation
  • 相关文献

参考文献9

  • 1Vanlet P, Horny HP, Bennet JM, et al. Definitions and standards in the diagnosis and treatment of myelodysplatic syndromes : Con- sensus statements and report from a working conference[ J ]. Leuk Res,2007,31 : 727 -736.
  • 2Greenberg P, Cox C, LeBeau MM, et al. International senring sys- tem for evaluating prognosis in myelodysplestic syndromes [ J ]. Blood,1997,89 : 2079 - 2088.
  • 3马军,王建祥,主编.造血系统疾病临床诊疗规范教程[M].北京:北京大学医学出版社,2009:548.
  • 4Steensma DP, Baer MR, Slack JL, et al. Muhicenter study of decitabine administered daily forSdays everygweeks to adults with Myelodysplastic syndromes:the alternative dosing for outpatients treatment (ADOPT) trial[ J ]. J Clin Oneol, 2009,27 ( 23 ) : 3842 - 3848.
  • 5Lubbert M,Sueiu S, Balia L, et al. Low -dose deeitabine versus best supportive elderly patients with intermediate - or high - risk myelodysplastie syndrome (MDS) ineligible for intensive chemo- therapy : final results of the randomized phase IU study of the euro- pean organisation for research and treatment of cancer Leukemia group and the german MDS studygroup[ J]. J Clin Oneol,2011, 29(15) :1987 - 1996.
  • 6Lee JH, Jang JH, Park ,I, et al. A prospective multicenter Obser- vational study of decitabine treatment in Korean patients with my- elodysplstic syndrome [ J ]. Haemat ologiea, 2011,96 ( 10 ) : 1441 - 1447.
  • 7Thomas XG, Dmoszynska A, Wierzbowska A, et al. Results from a randomized phase 11 trial of deeitabine versus supportive care or low - dose cytarabine for the treatment of older patients with new- ly diagnosed AML[ J]. J Clin Oneol,2011,29(suppl) : 6504.
  • 8Cashen AF, Schiller GJ, O 1)onnell MR, et al. Multicenter, Phase IT study of decitabine for the frstline treatment of older patients with acute myeloid leukemia[J]. J Clin Oncol,2010,28 (4) : 556 - 561.
  • 9邱仲川,徐旻.细胞因子在清肝化瘀汤治疗慢性粒细胞性白血病中的研究[J].上海医学,2001,24(3):161-162. 被引量:3

二级参考文献3

共引文献9

同被引文献86

引证文献7

二级引证文献47

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部